

Rocío), Lola Navarro Amuedo (Hospital Universitario Virgen del Rocío), and Julia Praena (Hospital Universitario Virgen del Rocío).

Conflicts of interest

LELC has served as scientific advisor for Novartis, speaker for MSD, Pfizer, Angelini, ViiV, Gilead and Correvio, and has served as trainer for MSD and ViiV. The rest of authors have no conflicts of interests to declare.

References

1. Ramirez JA, Musher DM, Evans SE, Dela Cruz C, Crothers KA, Hage CA, et al. Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies. *Chest*. 2020;16: S0012-3692(20)31681-0.
 2. Zetvera® (Ceftobiprole). Full prescribing information. Available at: <https://cima.aemps.es/cima/pdfs/es/ft/78691/78691.ft.pdf> [accessed 23.04.21].
 3. Jimidar I, Vermeersch H, Tinke A, Hickey MB, Golea DJ. Stability of ceftobiprole medocaril powder for injection in common fluids and containers [abstract P-54E]. Seattle, WA, 8–11 June: American Society of Health-System Pharmacists; 2008.
 4. López-Cortés LE, Ayerbe-García R, Carrasco-Hernández L, Fraile-Ramos E, Carmona-Caballero JM, Quintana-Gallego E, et al., DOMUS OPAT Group. Outpatient parenteral antimicrobial treatment for non-cystic fibrosis bronchiectasis exacerbations: a prospective multicentre observational cohort study. *Respirition*. 2019;98:294–300.
 5. Pfaller MA, Flamm RK, Mendes RE, Streit JM, Smart JL, Hamed KA, et al. Ceftobiprole activity against Gram-positive and negative pathogens collected from the United States in 2006 and 2016. *Antimicrob Agents Chemother*. 2018;63:e01566–1618.
- Luis Eduardo López-Cortés ^{a,*}, Laura Herrera-Hidalgo ^b, Virginia Almadana ^c, María Victoria Gil-Navarro ^b, on behalf of the DOMUS OPAT Group ¹
- ^a Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen Macarena/CSIC/Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain
- ^b Unidad de Gestión Clínica de Farmacia, Hospital Universitario Virgen del Rocío/CSIC/Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain
- ^c Unidad Clínica de Neumología, Hospital Universitario Virgen Macarena, Seville, Spain
- * Corresponding author.
E-mail address: luislopezcortes@gmail.com (L.E. López-Cortés).
- ¹ A list of the authors DOMUST OPAT Group is provided in the appendix.
- <https://doi.org/10.1016/j.eimc.2021.05.002>
0213-005X/ © 2021 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved.

Obturator internus pyomyositis: not everything is septic arthritis



Piomiositis del músculo obturador interno: no todo es artritis séptica

Pyomyositis is a bacterial infection of the striated muscle, which usually develops into a muscle abscess. It mainly affects the large muscles of the lower limbs,^{1,2} and its location in the obturator internus muscle (OIM) is exceptional, little documented and a real diagnostic challenge.

We present the case of a 15-year-old adolescent boy, who came to the Emergency Department with a one-week history of fever, pain in the right gluteal region and a limp. He did not report any trauma, recent intense physical exercise or any previous infectious process. On examination, an antalgic position was observed with the right hip in flexion, external rotation and abduction. Blood tests showed 70.6% of neutrophils without leukocytosis (7.6–10⁹/l) and CRP of 8.9 mg/dl. X-rays of the pelvis and hips were performed without relevant findings and an ultrasound of the hip revealed joint effusion. The patient was admitted with clinical suspicion of septic arthritis.

Arthrocentesis was performed, with negative gram stain and culture results. Blood cultures were positive for methicillin-sensitive *Staphylococcus aureus* (MSSA), and treatment with intravenous cloxacillin was started. An abdominal ultrasound study was completed, which ruled out appendicitis, and an MRI of the hip

showed oedema of the peritrochanteric soft tissues without signs of septic arthritis. A follow-up MRI repeated five days later revealed an abscess measuring 6 × 1.5 × 5.5 cm in the OIM with probable associated pelvic osteomyelitis (Fig. 1). Ultrasound-guided drainage of the collection was performed, obtaining 12 cm³ of purulent fluid and culture isolation of MSSA (identical sensitivity to blood cultures). In turn, antibiotic treatment was extended with vancomycin and clindamycin, after withdrawing cloxacillin.

The clinical response and test results were favourable, but without complete resolution in successive follow-up MRIs, so it was decided to prolong parenteral treatment for six weeks, the first four weeks in hospital, and at discharge, two more weeks with weekly dalbavancin combined with oral clindamycin.

Primary pyomyositis is an infrequent condition, which is observed mainly in tropical climates, although in recent decades it has notably increased in our setting, associated above all with situations of immunosuppression.^{2–4}

Its pathogenesis is not completely known, but it has traditionally been associated with local trauma (15–50%) or strenuous physical exercise.^{1–5} It usually originates from haematogenous dissemination, with gram-positive bacteria being responsible for practically all cases, and *Staphylococcus aureus* being the most frequent microorganism.^{2,4}

Obturator internus pyomyositis (OIP) is an extremely rare condition of which few cases have been described in the literature. However, its incidence has been increasing in recent years.^{3,5} It is more common in children,^{1,5} and usually manifests with fever, pain in the hip or thigh, limp and antalgic position with the hip in flexion, external rotation and abduction.^{1,5} In half of the cases, it is complicated by infection of adjacent muscles or pelvic osteomyelitis,^{1,5} as occurred in our case.

☆ Please cite this article as: Martínez-Fernández S, Vázquez-Temprano N, Díz J. Piomiositis del músculo obturador interno: no todo es artritis séptica. *Enferm Infecc Microbiol Clin*. 2022;40:400–401.



Figure 1. Pelvic MRI. A. With contrast (gadolinium) and T1 enhanced. B. STIR sequence. Collection in right OIM of $6 \times 1.5 \times 5.5$ cm, with peripheral enhancement (A) and signal hyperintensity (B). Signal alteration in the ischial tuberosity that enhances with contrast (A).

Diagnosis is usually late due to clinical and analytical non-specificity,³ or as a result of being confused with other osteoarticular or intra-abdominal pathologies, especially septic coxarthriti^s.^{1,3,6} Ultrasound is useful as a diagnostic approach but the gold standard is MRI, which has great sensitivity and specificity, especially in early stages.^{3,6,7} It is also important to perform blood cultures and cultures of material drained from the abscess.

The duration of treatment is not well defined and will vary depending on the severity and response. Patients should be covered empirically for *Staphylococcus aureus* (and if immunocompromised also for gram-negative bacteria),^{2,7} initially intravenously, with subsequent oral sequencing. In addition, if an abscess appears it should be drained, with percutaneous drainage being preferable to surgery.² The usefulness of the new antistaphylococcal antibiotics, specifically dalbavancin, should be highlighted due to its convenient weekly intravenous dosage, which allows it to be administered on an outpatient basis. Although there is little experience in paediatric patients, it appears to be safe and effective,⁸ and given the higher incidence of this pathology at an early age, it has been interesting to see the excellent results obtained with our patient.

Therefore, we are facing an underdiagnosed disease, in which clinical suspicion will be fundamental, so when faced with a patient, especially a paediatric patient, who presents with fever, limp and a hip ultrasound that is normal or suggestive of septic arthritis, we should always suspect OIP and expand the study with MRI. In this way, we will avoid therapeutic delays and devastating complications, since the only prognostic factor for complete functional recovery is early diagnosis and treatment.³

Conflicts of interest

The authors have no conflicts of interest to declare.

References

- Viani RM, Bromberg K, Bradley JS. Obturator internus muscle abscess in children: report of seven cases and review. Clin Infect Dis. 1999;28:117–22, <http://dx.doi.org/10.1086/515080>.
- Crum NF. Bacterial pyomyositis in the United States. Am J Med. 2004;117:420–8, <http://dx.doi.org/10.1016/j.amjmed.2004.03.031>.
- Kiran M, Mohamed S, Newton A, George H, Garg N, Bruce C. Pelvic pyomyositis in children: changing trends in occurrence and management. Int Orthop. 2018;42:1143–7, <http://dx.doi.org/10.1007/s00264-017-3746-1>.
- Christin L, Sarosi GA. Pyomyositis in North America: case reports and review. Clin Infect Dis. 1992;15:668–77, <http://dx.doi.org/10.1093/clind/15.4.668>.
- Yahalom G, Guranda L, Meltzer E. Internal obturator muscle abscess caused by *Klebsiella pneumoniae*. J Infect. 2007;54:157, <http://dx.doi.org/10.1016/j.jinf.2006.09.011>.
- Unnikrishnan PN, Perry DC, George H, Bassi R, Bruce CE. Tropical primary pyomyositis in children of the UK: an emerging medical challenge. Int Orthop. 2010;34:109–13, <http://dx.doi.org/10.1007/s00264-009-0765-6>.
- Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJC, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:10, <http://dx.doi.org/10.1093/cid/ciu296>.
- Gonzalez D, Bradley JS, Blumer J, Yogev R, Watt KM, James LP, et al. Dalbavancin pharmacokinetics and safety in children 3 months to 11 years of age. Pediatr Infect Dis J. 2017;36:645–53, <http://dx.doi.org/10.1097/INF.0000000000001538>.

Sandra Martínez-Fernández ^{a,*}, Nuria Vázquez-Temprano ^b,
Julio Diz ^b

^a Servicio de Dermatología, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain

^b Servicio de Medicina Interna, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain

* Corresponding author.

E-mail address: [\(S. Martínez-Fernández\).](mailto:sandra.martinez.fernandez@sergas.es)

<https://doi.org/10.1016/j.eimce.2022.04.003>

2529-993X/ © 2021 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved.